BUMA PHARMA
Sources: the KBO register on 20-11-2026; the National Bank, 2025 annual accounts filed on 05-08-2026; the Belgian Official Gazette, latest deed of 05-07-2023.
Grounds
the facts the verdict rests on, each with its source- BUMA PHARMA made a profit in every financial year since 2023.Annual accounts 2023 to 2025 page 2
- Equity stands at €38,507, or 67.3% of the balance sheet total of €57,247. The solvency of 67.3% is higher than at 78% of the 25,414 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
- BUMA PHARMA paid out €833 in dividends, 6% of the profit of 2025.Annual accounts 2025 page 2
- The 2025 accounts reached the National Bank on 05-08-2026, 5 days after the term.National Bank, filing of 05-08-2026 page 4
Representation
The signing rule is in the deed of 05-07-2023.
Articles of association, Belgian Official Gazette of 05-07-2023, deed 23366510
Ownership
The accounts in the micro format list no shareholders. holds all 100 shares.
Deed of 05-07-2023
Financial situation
Annual accounts 2023 to 2025, as filed with the National Bank
Gross margin and net resultin euro
Equity and debtsin euro
Cashin euro
| Financial year | 20235 months | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Results | ||||
| Gross margin | €14,894 | €22,990 | €22,296 | |
| Operating result | €13,684 | €21,677 | €20,857 | |
| Net result | €9,918 | €15,368 | €14,746 | |
| Balance sheet at the closing date | ||||
| Equity | €10,085 | €24,593 | €38,507 | |
| Debts | €14,325 | €16,754 | €18,740 | |
| Debts due within one year | €14,314 | €16,754 | €18,740 | |
| Cash | €20,400 | €37,802 | €55,063 | |
| Balance sheet total | €24,410 | €41,347 | €57,247 | |
| Ratios | ||||
| Solvency | 41.3% | 59.5% | 67.3% | |
| Liquidity | 1.43 | 2.26 | 2.94 | |
Source: Annual accounts 2025, micro format, filed on 05-08-2026 (2026-00390280); Annual accounts 2024, micro format, filed on 30-08-2025 (2025-00476101); Annual accounts 2023, filed on 30-08-2024 (2024-00453593).
Debts rose by €1,986 in 2025, of which €161 to suppliers. A dividend stands among the debts on the balance sheet date until it is paid.
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
BUMA PHARMA states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from €22,990 to €22,296.
The financial year to 31-12-2023 ran for 5 months.
Board, signature and ownership
Position on 20-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
The signing rule is in the deed of 05-07-2023.
Articles of association, Belgian Official Gazette of 05-07-2023, deed 23366510
Board
one director in officeOwnership and group
Shareholders
The accounts in the micro format list no shareholders. holds all 100 shares.
Deed of 05-07-2023
Events and comparison
Every event since the founding, newest first
Annual accounts 2025 filed, 5 days late.
NBB filingAnnual accounts 2024 filed, 30 days late.
NBB filingHighest result from 2023 to 2025. The operating result of €21,677 and the net result of €15,368 are both a record.
FinancialAnnual accounts 2023 filed, 30 days late.
NBB filingIncorporation. Founding capital of €1,000, 100 shares. Founded by . appointed as director. Published on 05-07-2023.
Gazette, deed 23366510First establishment. Oudestraat 121, Antwerp.
Comparable companies, two years later
In July 2024, 39,332 companies had the same profile as BUMA PHARMA has now: micro, 2 to 5 years old, solvency 30% or more and a profit of 5% of the balance sheet or more. Two years later 95.7% were still trading, 2.5% had stopped another way and 1.8% had gone bankrupt.
The return on assets of BUMA PHARMA, 25.8%, is higher than at 89% of the 24,603 companies filing micro accounts in retail trade (NACE 47) in 2025.
Other findings
Peppol
Reachable for e-invoices since 07-12-2025, under 0208:0803488513.
Sanctions lists
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 20-11-2026 | KBO 0803.488.513 |
| National Bank of Belgium | Annual accounts 2025, micro format | 05-08-2026 | 2026-00390280 |
| National Bank of Belgium | Annual accounts 2024, micro format | 30-08-2025 | 2025-00476101 |
| National Bank of Belgium | Annual accounts 2023 to 2023 | 30-08-2024 | 2024-00453593 |
| Belgian Official Gazette | Articles of association with the signing rule | 05-07-2023 | deed 23366510 |
| Peppol Directory | Registration for e-invoices | 07-12-2025 | 0208:0803488513 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 19-11-2026 | |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 19-11-2026 | bankruptcy model of 2 October 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 19-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.